Clinical Trial Update: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib [Phase 2]

View source ↗

Summary

A Phase 2 trial of single-agent glasdegib in myelofibrosis patients previously treated with ruxolitinib was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Glasdegib (glasdegib)

Snippet

Sponsor: Pfizer | Conditions: Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2018-04-02